

PROGRAM

Spring Triple Negative Breast Cancer **Symposium**

Unraveling Tumor
Heterogeneity
to Reach the Cure

Seville, April 10th 2026

Scientific coordinators

Ana Garrido-Castro

Assistant Professor of Medicine, Harvard Medical School.
Director, Triple-Negative Breast Cancer Research, Susan F. Smith Center for
Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute.

Luis de la Cruz Merino

Full Professor of Medicine, University of Seville. Chief, Clinical Oncology
Department, Virgen Macarena University Hospital, Sevilla

Fernando Henao Carrasco

Director, Breast Cancer Unit and Hereditary Cancer Program.
Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla

Venue

Instituto de Biomedicina de Sevilla
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot s/n. Sevilla

Seville, April 10th 2026

10:15 – 10:25 **Welcome and opening remarks**

Ana Garrido-Castro. Assistant Professor of Medicine, Harvard Medical School. Director, Triple-Negative Breast Cancer Research, Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Luis de la Cruz Merino. Full Professor of Medicine, University of Seville. Chief, Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla

Fernando Henao Carrasco. Director, Breast Cancer Unit and Hereditary Cancer Program. Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla

10:25 – 11:45 **Understanding the biological complexity of TNBC**

Chairs: Antoni Celià-Terrassa, Cancer Stem Cells & Metastasis Dynamics Lab, Hospital del Mar Medical Research Institute (IMIM), Barcelona

Luis de la Cruz, Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla

10:25 – 10:40 **Histopathologic diversity in Triple-Negative Breast Cancer**

Federico Rojo, Anatomical Pathology Service. Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD), Madrid

10:40 – 10:55 **Molecular classification, TNBC Subtypes, and the role of TILs**

Roberto Leon-Ferre, Division of Medical Oncology. Mayo Clinic, Rochester, USA

10:55 – 11:10 **Immune taxonomy of TNBC: immunogenic cell death and the tumor microenvironment**

Carlos del Fresno, Innate Immune Response Research Group, Instituto de Investigación Sanitaria Hospital la Paz-IdiPAZ, Madrid

11:10 – 11:25 **Translational implications: bringing tumor biology into treatment decisions**

Javier Pascual, Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga

11:25 – 11:45 **Discussion and Q&A**

11:45 – 12:15 **Coffee Break**



Seville, April 10th 2026

12:15 – 13:45 **Personalizing treatment in early-stage TNBC**

Chairs: Ander Urrutikoetxea, Medical Oncology Department, Gipuzkoa Cancer Unit. Osakidetza-BioGipuzka.

Manuel Ruiz, Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla

12:15 – 12:30 **Neoadjuvant immunotherapy: lessons learned and open questions from KEYNOTE-522**

Fernando Moreno, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

12:30 – 12:45 **Neoadjuvant immunotherapy strategies beyond KEYNOTE-522**

Heather McArthur, Breast Cancer Program, Simmons Comprehensive Cancer Center, Dallas, USA

12:45 – 13:00 **Pathologic complete response and ctDNA: new tools to refine TNBC treatment**

Stefania Morganti, Research Fellow, Dana-Farber Cancer Institute, Boston, USA

13:00 – 13:15 **Optimizing adjuvant systemic therapy for early TNBC**

Sara López-Tarruella, Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid

13:15 – 13:45 ***Discussion and Q&A***

13:45 – 15:00 **Working Lunch**

15:00 – 16:30 **Therapeutic advances in metastatic TNBC: IO, ADCs and Beyond**


Chairs: Ana Garrido-Castro, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, USA

Juan de la Haba, Medical Oncology Department, Hospital Universitario Reina Sofia, Córdoba

15:00 – 15:15 **Harnessing the immune system to treat metastatic TNBC**

Giuseppe Curigliano, University of Milan and European Institute of Oncology, IRCCS Milan, Italy

ONLINE
PARTICIPATION



Seville, April 10th 2026

- 15:15 – 15:30 **ADCs in TNBC: first-line strategies**
Ana Garrido-Castro, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, USA
- 15:30 – 15:45 **ADCs in TNBC: second-line options and ADC sequencing**
Joaquín Gavilá, Medical Oncology Department, Instituto Valenciano de Oncología – IVO, Valencia
- 15:45 – 16:00 **Predictive biomarkers in the ADC era**
Mafalda Oliveira, Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona
- 16:00 – 16:30 *Discussion and Q&A*
- 16:30 – 17:15 **Interactive clinical cases: real-world TNBC case challenges**
Chairs: Alejandro Falcón, Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla
Fernando Henao Carrasco, Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla
- 16:30 – 16:45 **Case 1: early-stage TNBC with residual disease after neoadjuvant therapy**
- 16:45 – 17:00 **Case 2: metastatic TNBC after Sacituzumab**
- 17:00 – 17:15 *Discussion - Audience participation (interactive voting via QR)*
- 17:15 – 17:45 **Coffee Break**
- 17:45 – 19:15 **Shaping the future of TNBC: from hereditary risk to novel targets**
Chairs: Agostina Stradella, Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat
Christos Sotiriou, Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium
- 17:45 – 18:00 **Hereditary predisposition and BRCA in TNBC: therapeutic implications**
Judith Balmaña, Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona

Seville, April 10th 2026

- 18:00 – 18:15 **Transcriptomic classification and emerging targets**
Miguel Ángel Quintela, Clinical Research Program, Spanish National Cancer Research Centre (CNIO), Madrid
- 18:15 – 18:30 **Spatial imaging and computational approaches to develop personalized therapeutic strategies for TNBC**
Christos Sotiriou, Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium
- 18:30 – 18:45 **Emerging therapies in metastatic TNBC: how will the treatment algorithm change in 3 years?**
Antonio Giordano, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, USA
- 18:45 – 19:15 ***Discussion and Q&A***
- 19:15 – 19:30 **Closing remarks**
Ana Garrido-Castro. Assistant Professor of Medicine, Harvard Medical School. Director, Triple-Negative Breast Cancer Research, Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
Luis de la Cruz Merino. Full Professor of Medicine, University of Seville. Chief, Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla
Fernando Henao Carrasco. Director, Breast Cancer Unit and Hereditary Cancer Program. Clinical Oncology Department, Virgen Macarena University Hospital, Sevilla

Spring Triple Negative Breast Cancer Symposium

Unraveling Tumor Heterogeneity to Reach the Cure

Seville, April 10th 2026

Organized by:

saom

Sociedad andaluza de oncología médica

SPONSORS

GOLD



Oncology

SILVER



BRONZE



AUSPICES



SOLTI



Secretaría técnica

tactics

Barcelona - Madrid

93 451 17 24

info@tacticsmd.net

www.tacticsmd.net